HC Wainwright Cuts Earnings Estimates for Wave Life Sciences

Wave Life Sciences Ltd. (NASDAQ:WVE) – Investment analysts at HC Wainwright lowered their FY2025 earnings estimates for shares of Wave Life Sciences in a research note issued on Wednesday, March 5th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.87) per share for the year, down from their previous estimate of ($0.74). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Wave Life Sciences’ FY2026 earnings at ($1.07) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at $0.71 EPS.

Wave Life Sciences (NASDAQ:WVE) last posted its earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.34. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. The company had revenue of $83.75 million during the quarter, compared to analyst estimates of $25.60 million.

A number of other brokerages also recently commented on WVE. Jefferies Financial Group began coverage on shares of Wave Life Sciences in a report on Tuesday, February 25th. They issued a “buy” rating and a $26.00 target price for the company. StockNews.com raised shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday. Truist Financial increased their target price on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Finally, Mizuho lifted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Wave Life Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Wave Life Sciences Price Performance

Shares of NASDAQ WVE opened at $9.40 on Friday. Wave Life Sciences has a 1-year low of $4.25 and a 1-year high of $16.74. The business has a fifty day moving average price of $11.44 and a 200 day moving average price of $11.21. The stock has a market capitalization of $1.43 billion, a P/E ratio of -8.47 and a beta of -1.09.

Hedge Funds Weigh In On Wave Life Sciences

Institutional investors have recently bought and sold shares of the business. Maverick Capital Ltd. increased its stake in shares of Wave Life Sciences by 31.0% in the third quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company’s stock worth $82,390,000 after acquiring an additional 2,378,159 shares during the period. Driehaus Capital Management LLC boosted its holdings in Wave Life Sciences by 14.6% in the fourth quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company’s stock valued at $83,033,000 after purchasing an additional 853,589 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Wave Life Sciences by 63.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company’s stock worth $63,074,000 after purchasing an additional 1,972,262 shares during the period. Vanguard Group Inc. raised its stake in shares of Wave Life Sciences by 10.2% during the 4th quarter. Vanguard Group Inc. now owns 3,182,512 shares of the company’s stock valued at $39,368,000 after buying an additional 294,956 shares during the last quarter. Finally, Emerald Advisers LLC lifted its holdings in shares of Wave Life Sciences by 9.7% in the 4th quarter. Emerald Advisers LLC now owns 3,162,369 shares of the company’s stock valued at $39,119,000 after buying an additional 280,859 shares during the period. 89.73% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Wave Life Sciences

In other news, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the transaction, the chief executive officer now directly owns 338,351 shares in the company, valued at $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 29.10% of the company’s stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.